FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - February 11, 2026 161 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CEPHEUS study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Patient Guide on Cancer Pain Management Now Available Also in French December 16, 2025 After Spine Tumor, Teacher Goes On Mission To Serenade Hospital Patients... June 24, 2019 New obesity strategy is a ‘landmark day for the nation’s health’... July 27, 2020 Gilteritinib Improves Survival in AML with FLT3 Mutations November 27, 2019 Load more HOT NEWS New on NCI’s Websites for September 2022 COVID Vaccine Basics for Cancer Patients Activity and Manageable Toxicity of Pembrolizumab in Some Rare and Ultrarare... Consistent Efficacy Benefit with Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Patients...
